Pharmacologic treatments for covid-19 patients
Methods
Protocol amendment:
As of December 14, 2022, the COVID-NMA revised its protocol and stopped including pharmacological interventions trials. The analysis presented in this page includes trials identified and included up to December 14, 2022. Ofnote, different last search date are considered by category. We provide the updated results up to last search defined next to each comparison including all identified reports through our search strategy up to this date.
meta-COVID
Perform your own analysis using COVID-NMA data, create and download your forest plots by clicking below:
Summary of Main Results
Summary of the evidence for pharmacological treatment of hospitalized COVID-19 patients identified up to October 17, 2022 is available below.
For earlier editions of the summary of main results, click here
Treatment comparisons
Create and download your forest plots with the most up-to-date data here Forest plots
Access the forest plots for the 1 treatment comparisons .
Comparisons evaluating antivirals and immunomodulators with last search date December 14, 2022.
Anti-virals (1 comparisons)
Comparisons with last search date 28 February 2022 or as stated next to each comparison.
Search studies
General characteristics of primary studies
| Trial | Funding | Comparisons | Design | Participants | Sample size | Overall risk of bias Highest assessment |
Full description | |
|---|---|---|---|---|---|---|---|---|
| Treatment 1 | Treatment 2 | |||||||
| NCT04960202 EPIC-HR Hammond J, N Engl J Med, 2022 Full text Commentary |
Private |
Nirmatrelvir/ritonavir |
Placebo |
RCT | Outpatients with confirmed COVID-19 (mild) treated by 343 centers in 21 countries | N=2246 |
Some concerns Details |
|